Oxford Biomedica Share Price (OXB)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Oxford Biomedica	LSE:OXB	London	Ordinary Share	GB0006648157	ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-0.10p	-1.15%	8.60p	8.50p	8.65p	8.99p	8.60p	8.99p	533,220	10:18:30

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	27.8	-20.3	-0.6	-	265.60

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Valirx (VAL), Port Erin (PEBI)

Oxford Biomedica (OXB) Latest News (1)

Oxford Biomedica News

Date	Time	Source	Headline
23/8/2017	10:31	UKREG	Oxford Biomedica PLC Director Dealings / Market Share Purchase
22/8/2017	10:35	UKREG	Oxford Biomedica PLC Director Dealings / Market Share Sale and Purchase
17/8/2017	12:01	GLOBE	Oxford BioMedica plc: INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2017
17/8/2017	10:20	ALNC	Oxford Biomedica Loss Narrows As It Progresses Novartis Collaboration
17/8/2017	07:28	ALNCF	Alliance News Flash Headline
17/8/2017	07:00	UKREG	Oxford Biomedica PLC Interim Results
11/8/2017	09:24	ALNC	Oxford BioMedica To Collaborate On Gene And Cell Therapy Project
11/8/2017	07:00	RNSNON	Oxford Biomedica PLC OXB announces Innovate UK £2m collaboration
07/8/2017	10:46	ALNC	Oxford BioMedica Licensed To Manufacture Lentiviral Vector Material
07/8/2017	09:05	UKREG	Oxford Biomedica PLC Holding(s) in Company

More Oxford Biomedica News

Oxford Biomedica Takeover Rumours

Oxford Biomedica (OXB) Share Charts

1 Year Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

Intraday Oxford Biomedica Chart

Oxford Biomedica (OXB) Discussions and Chat

Oxford Biomedica Forums and Chat

Date	Time	Title	Posts
23/8/2017	11:14	Oxford Biomedica Bulls Only Thread	26,072
21/8/2017	17:20	OXFORD BIOMEDICA (OXB): MODERATED CHART AND DISCUSSION THREAD	72,878
06/7/2017	10:39	Only worth 1.25p on fundamentals....	22
24/12/2015	15:10	Oxford Biomedica Bears Only thread	5
18/7/2014	13:56	Welcome To The Greatest Short On ADVFN Sponsored By tony979 !	41

Add a New Thread

Oxford Biomedica (OXB) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
09:52:49	8.61	10,000	861.10	O
09:47:22	8.51	24,444	2,080.18	O
09:42:19	8.55	8,381	716.32	O
09:41:17	8.61	948	81.63	O
09:28:21	8.61	11,497	990.01	O

View all Oxford Biomedica trades in real-time

Oxford Biomedica (OXB) Top Chat Posts

Date	Subject
23/8/2017 09:20	Oxford Biomedica Daily Update: Oxford Biomedica is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 8.70p. Oxford Biomedica has a 4 week average price of 8.25p and a 12 week average price of 4.91p. The 1 year high share price is 11.25p while the 1 year low share price is currently 3p. There are currently 3,088,420,525 shares in issue and the average daily traded volume is 6,904,413 shares. The market capitalisation of Oxford Biomedica is £265,604,165.15. Read Full Thread Reply
13/7/2017 14:32	stocktastic: 'As for the IPO, a pet subject of yours, I can't think of a better example showing that when you raise something which is plainly tripe' Here is the basis for my speculation: - The OXB share price had risen phenomenally to 12p - Worldwide, there was a massive biotech IPO bubble going on, with the window wider than it has ever been - OXB was flagging how US listed comparators got much better valuations - OXB needed cash - OXB switched to Jeffries - a firm with great presence in the UK and EU as well as US - also one of the top firms for healthcare - Many of the directors all buying smallish sums around the same time at what were historically high price levels. No honest poster would call that 'tripe' So you just think it's a coincidence that most/all of the directors bought relatively small quantities of stock around the highs? You think OXB would be paying high rates of interest if they could have taken a rare opportunity to tap the US markets? Coincidence that OXB announced a fundraiser that included a private placing in the US, shortly after my IPO-failed speculation? My view on that was that they were making the most of parties that had become interested through a US listing attempt It's actually all quite plausible. Certainly no need to call it tripe Read Full Thread Follow Reply
12/7/2017 21:58	harry s truman: And a tweet from Novartis thanking the trial families for their support. I think there's a 50 / 50 chance that the OXB share price will go up tomorrow. Read Full Thread Follow Reply
11/7/2017 14:01	stocktastic: 'revisionist history' eh? Nothing revised there 'I must remember that escape for future reference - claim the other person raised it first' You're perhaps misinterpreting as I didn't do that at all.. Re IPO theory - I just reiterated it is MY opinion, but asked whether OXB could confirm it to be wrong when I speculate they tried to list in the US Then I said that I disagree with your view that they'd not be able to afford a US listing - since as explained, half the purpose of listing would be to raise cash. So where's the 'escape' and claiming someone else raised it first??? Look at my US listing theory this way - The OXB share price had risen phenomenally to 12p - Worldwide, there was a massive biotech IPO bubble going on, with the window wider than it has ever been - OXB was flagging how US listed comparators got much better valuations - OXB needed cash - OXB switched to Jeffries - a firm with great presence in the UK and EU as well as US - also one of the top firms for healthcare - Many of the directors all buying smallish sums around the same time at what were historically high price levels. So you're suggesting that the company took on loans at a high rate of interest rather than try and capitalise on a rare opportunity to list in the US on great terms? It actually seems rather unlikely to me that OXB didn't try to list in the US IMO the reason the company failed was the early stage of products, the past failures and the lower appetite for manufacturing/royalies vs more traditional biotech listings etc. Read Full Thread Follow Reply
06/7/2017 14:28	asat91: As I understand it, OXB are spending £40mill per year at the moment, and their revenue is about 20-30mill without CTL019. So if they make the £65mill/year estimated from CTL019, and maintain their current revenue and costs this would give a pre-tax profit of about £40mill/year. Earnings per share in that situation would be 40mill/3billion = 0.013. P/E ratio at current share price would be 7.5, which as marcus says would be very low for a promising biotech company in oncology gene therapy, especially a biotech company that is so valuable to a giant like Novartis. Expect a P/E ratio of between 15 and 25 by December 2017 or by December 2018 when they release their profits (assuming approval and sales of CTL019) which would give a share price of 25p+. Better investment than any bank account that's for sure! Even if we will have to wait until Dec 18 for the profit statement after CTL019 has been selling a while. And of course with good news coverage, positive broker reports and popularity comes market hysteria which could even push the share price up to something ridiculous like 40p or 50p at some point next year. I wasn't around for Trovax but I assume that's what happened there? If Novartis do decide to buy/acquire OXB at some point over the next year or two, we could be looking at a sale price of close to £1billion which Novartis can easily afford with cash reserves of £14billion+, and would be more than 3x current OXB share price. What do you guys think? Read Full Thread Follow Reply
02/7/2017 18:54	gareth jones: I fear for the OXB share price in the morning given all this good news! Seriously we should see good volume and hopefully a positive share price leading up to the FDA meeting on 12th. If we dont get an announcement/decision on 12th we may see a draw back as short termers have to bail out but it should make little difference to all LTH's. MM's will earn their money in the next couple of weeks as they respond to market sentiment and demand in setting buy/sell prices. Read Full Thread Follow Reply
22/6/2017 15:43	rrr: While I agree the main point is about patients, as you ask I think it will get approval and that that will be good for OXB share price (but to what extent I leave to others). rrr Read Full Thread Follow Reply
22/6/2017 12:05	rrr: marcus thank you! I am just so excited by this, it is so utterly amazing. I'm not talking about the OXB share price, I'm talking about the medicine and the patients, who could easily be any of us. These are sounding suspiciously like cures - for the previously incurable. utterly amazing and wonderful Read Full Thread Follow Reply
31/3/2017 19:04	sddavies1: Its a frustrating shame that, despite Novartis delivering on their promises for something that is key to our future, the OXB share price is still languishing below its recent highs.Instead of remaining silent. Its high time BoD started to make noises about how they plan to deal with the debt that has cast a shadow over proceedings.I know that everything is starting to look rosy on paper but to me it seems that unless they start to add capital value soon, we will be sittings ducks for a nice cheap buy out. Read Full Thread Follow Reply
30/1/2017 19:38	beanol: Yes Marcus indeed. Very promising. BUT why with all this positive news and it being fairly clearly known that Oxb has a role to play which will hugely benefit the company has there been no upwards movement in the Oxb share price - aren't markets supposed to rise ahead of major announcements? Or is the market so mistrustful of Oxb management and its past record that..... Read Full Thread Follow Reply
22/1/2017 01:10	beanol: HarryFrom reading your always thoughtful and considered posts for years I know you have a deep well of understanding about Oxb which the rest of us profit from and I certainly for one will never rival or come near. But right now (2017) there's a business imperative on the march - Novartis and Car T therapy : I am clear from a combination of the following: letter LT wrote following two specific complaints I made, speaking to people connected to Novartis, others involved in the haplessly managed fund raising last year that this year if not now or never for Oxb will certainly be pretty critical for the company. No substantive progress for Novartis no progression for Oxb share price. But if progress for Novartis and Car T then we get into a virtuous circle which will per force mean a closer relationship or more with Novartis. Given what the latter have riding on Car T there is likely to be no other alternative. I can't believe Trovax or any other drug from Oxb's stable will (really) come into the reckoning. Time will tell obviously but let's see where we are end of April. In writing this I realise I am becoming a one trick pony but in spite of its pretensions to wider success so I'm afraid Oxb may be becoming too. Read Full Thread Follow Reply

Oxford Biomedica share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:40 V: D:20170823 10:14:24